Rescue of Dendritic Cells from Glycolysis Inhibition Improves Cancer Immunotherapy in Mice

Strategic Insights -

Researchers from Arizona State University have discovered a strategy to rescue dendritic cells from glycolysis inhibition, which improves cancer immunotherapy in mice. This breakthrough involves inhibiting glycolysis in cancer cells using PFK15, while simultaneously rescuing glycolysis in dendritic cells (DCs) using fructose-1,6-biphosphate (F16BP). The research, published in Nature Communications, demonstrated that this approach improves the survival of mice and generates cytotoxic T cell responses by elevating Tc1 and Tc17 cells within the tumor.

Key Takeaways:

  • Researchers from Arizona State University have developed a strategy to inhibit glycolysis in cancer cells using PFK15, while rescuing glycolysis in dendritic cells using F16BP.
  • The approach improved the survival of mice and generated cytotoxic T cell responses by elevating Tc1 and Tc17 cells within the tumor.
  • The research demonstrated the feasibility of this strategy in challenging and established YUMM1.1 tumors in immunocompetent female mice.
  • The study showed that F16BP vaccine formulations can rescue DCs in vitro and in vivo, and test the versatility of this strategy in adoptive DC therapy.
  • The research provides a new approach for rescuing glycolysis of DCs using metabolite-based formulations to generate immunotherapy.

Statistics:

  • The study tested the approach in challenging and established YUMM1.1 tumors in immunocompetent female mice.
  • The research generated cytotoxic T cell responses by elevating Tc1 and Tc17 cells within the tumor.
  • The approach improved the survival of mice.
  • The study demonstrated the feasibility of this strategy in vivo.

Sources:

  • NewsRx. Arizona State University Researchers Release New Study Findings on Vaccines. Vaccine Weekly. September 20, 2023; p 18.
  • Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice. Nature Communications, 2023,14(1):1-12. (Nature Communications - https://www.nature.com/ncomms/).
  • Nature Portfolio.